Results support international multi-centre program for product commercialisation
Melbourne, Australia; 6 August 2008: The Royal Melbourne Hospital and Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today jointly announced successful results from the long bone fracture repair clinical trial using Mesoblast's proprietary adult stem cell technology.
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that its second generation, influenza treatment, CS-8958, has successfully completed its initial Phase II clinical evaluation, showing favourable outcomes against all measured endpoints. The initial Phase III trial is scheduled to commence later this year. CS-8958 is a long acting neuraminidase inhibitor (LANI), and is co-owned with Daiichi-Sankyo Company Limited (TYO:4568).
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that it had received written notification from GlaxoSmithKline (GSK) that indicative royalties from Relenza were $0.4m during the three months ended 30 June 2008, on sales of $6.2m.
Helicon Group Limited (ASX:HCG) is pleased to announce that earlier this month the Chinese State Food and Drug Administration (SFDA) granted approval for the skin regeneration concept and device, ReCell(R), for sale in China.
Neuren Pharmaceuticals (ASX:NEU)(PINK:NURPF) announced today that Glypromate(R) and NNZ-2566 for neuroprotection in cardiopulmonary bypass and traumatic brain injury (TBI) have been selected as one of the Top 10 most promising neuroscience projects available for partnering by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.
The CEO Transcript - Investor Briefing with Silviu Itescu, Founder and Executive Director, Mesoblast Limited (ASX:MSB)(PINK:MBLTY) 21 July 2008.
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced it had concluded its litigation against GlaxoSmithKline (GSK). The announcement followed formal mediation between by the parties ordered by the Victorian Supreme Court. The mediation provided the parties with the opportunity to resolve their differences and eliminate the uncertainty and costs associated with the legal process.
